CHOLINE C-11

Details

Stereochemistry	ACHIRAL
Molecular Formula	C5H14NO
Molecular Weight	103.1715
Optical Activity	NONE
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	1

SHOW SMILES / InChI

Structure Search

SMILES

C[N+](C)([11CH3])CCO

InChI

InChIKey=OEYIOHPDSNJKLS-BJUDXGSMSA-N

InChI=1S/C5H14NO/c1-6(2,3)4-5-7/h7H,4-5H2,1-3H3/q+1/i1-1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28723716 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203155s000lbl.pdf

Choline C 11 injection was approved to help diagnose recurrent prostate cancer. It is used for a procedure called positron emission tomography (PET) scan to detect tumors that are not detectable by other scanning procedures, such as bone scan, computed tomography (CT), or magnetic resonance imaging (MRI). Choline C 11 is a radioactive diagnostic agent, the analog of choline. Choline is involved in the synthesis of the structural components of cell membranes, as well as modulation of transmembrane signaling. Increased phospholipid synthesis (i.e., increased uptake of choline) has been associated with cell proliferation and the transformation process that occurs in tumor cells. Recently, Choline C 11 PET was studied for diagnosis the patients with hepatocellular carcinoma; although the phase II of clinical trials was not begun.

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Prostate cancer 186 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203155s000lbl.pdf	Diagnostic		Approved 8583	CHOLINE C-11 Approved Use Choline C 11 Injection is indicated for positron emission tomography (PET) imaging of patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging (MRI). In these patients, 11 C-choline PET imaging may help identify potential sites of prostate cancer recurrence for subsequent histologic confirmation. Suspected prostate recurrence is based upon elevated blood prostate specific antigen (PSA) levels following initial therapy. In clinical studies, images were produced with PET/CT coregistration. Launch Date 2012
Hepatocellular carcinoma 83 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28723716	Diagnostic		Phase II 1147	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
11C-Choline-Pet Guided Stereotactic Body Radiation Therapy for Lymph Node Metastases in Oligometastatic Prostate Cancer.	2017-10-21	28980836
Refining the management of patients with hepatocellular carcinoma integrating 11C-choline PET/CT scan into the multidisciplinary team discussion.	2017-10	28723716
11C-choline PET/CT and whole-body MRI including diffusion-weighted imaging for patients with recurrent prostate cancer.	2017-09-12	29029532
Contribution of 11C-Choline PET/CT in prostate carcinoma biochemical relapse with serum PSA level below 1 ng/ml.	2017-07-11	29137875

Sample Use Guides

In Vivo Use Guide

The recommended dose is 370 to 740 MBq (10 to 20 mCi) administered as a bolus intravenous injection. The radioactivity dose (370 to 740 MBq, 10 to 20 mCi) is chosen based on patient body dimensions and the characteristics of the image acquisition system.

Route of Administration: Intravenous

In Vitro Use Guide

Unknown

Name

Type

Language

CHOLINE C-11 CATION

Preferred Name

English

CHOLINE C-11

Common Name

English

CHOLINE C-11 ION

Common Name

English

CHOLINE C-11 [ORANGE BOOK]

Common Name

English

Choline (11C) [WHO-DD]

Common Name

English

ETHANAMINIUM, 2-HYDROXY-N,N-DIMETHYL-N-(METHYL-11C)-

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000177914